INVO News & Events

INVO Fertility entered into a warrant inducement agreement with an investor for the immediate exercise of certain outstanding warrants that the Company issued on December 3. Pursuant to a warrant inducement agreement, the Investor has agreed to a reduced exercise price of the outstanding December 2025 Warrants to an amended exercise price of $1.59, and to exercise the outstanding December 2025 Warrants to purchase an aggregate of 4,733,728 shares of the Company's common stock at the amended exercise price of $1.59. The gross proceeds from the exercise of the warrants are expected to be approximately $7.5M, prior to deducting financial advisory fees and estimated offering expenses. Maxim Group is acting as the exclusive Financial Advisor for the transaction. In consideration for the immediate exercise of the existing warrants, the Company also agreed to issue to the investor unregistered warrants to purchase an aggregate of 9,467,456 shares of the Company's common stock with an exercise price of $1.59 per share. The New Warrants will be subject to shareholder approval and will expire on the five and one-half year anniversary from the date of shareholder approval. The Company has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issuable upon exercise of the New Warrants. The closing of the warrant exercise transactions is expected to occur on or about January 30, 2026, subject to satisfaction of customary closing conditions.

INVO Fertility files to sell 7.37M shares of common stock for holders

INVO Fertility entered into a securities purchase agreement with a single institutional investor to purchase 2,366,864 shares of common stock together with warrants to purchase up to an aggregate 4,733,728 shares of common stock, in a private placement priced at-the-market under Nasdaq rules. The combined effective offering price for each share of common stock and accompanying warrants is $1.69. The warrants will have an exercise price of $1.69 per share, will be exercisable upon shareholder approval and will expire on the five year anniversary from such date of shareholder approval. The gross proceeds to the Company from the Offering are estimated to be approximately $4M before deducting the placement agent's fees and other estimated Offering expenses. The Offering is expected to close on or about December 3, 2025, subject to the satisfaction of customary closing conditions. Maxim Group is acting as the sole placement agent in connection with the Offering.